Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | BLK | P51451 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994712 | 0.80 | KIT (0.55) | KITBLKBTKLCK | |
| SCHEMBL5997079 | 0.73 | LCK (0.44) | KITBLKALDH1A1RAB9ATDP1 | |
| SCHEMBL5995311 | 0.67 | SRC (0.54) | KITBLKBTKLCK | |
| SCHEMBL5997433 | 0.67 | LCK (0.45) | BLKBTKLCK | |
| SCHEMBL15824391 | 0.66 | KIT (0.74) | KITBLKALDH1A1BTKLCK | |
| SCHEMBL5997067 | 0.65 | SRC (0.55) | — | |
| SCHEMBL4379855 | 0.63 | JAK2 (0.59) | ALDH1A1 | |
| SCHEMBL17915907 | 0.63 | JAK3 (0.49) | BLKBTKLCKMAPK1 | |
| SCHEMBL15998133 | 0.63 | BTK (0.72) | BLKBTK | |
| SCHEMBL12111065 | 0.63 | JAK3 (0.49) | BLKBTKLCKMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | KIT 209/4885BLK 123/4885ALDH1A1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.